医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

 Genetron Health Announces Strategic Collaboration with CStone

2019年12月13日 PM11:05
このエントリーをはてなブックマークに追加


 

BEIJING

Recently, Genetron Health has announced strategic collaboration with CStone Pharmaceuticals (“CStone”), providing companion diagnostic development services and clinical sample testing services for the oncological targeting pharmaceutical R&D of CStone, in order to boost efficiency of new medicine development and its approval processes.

Based on diverse testing platforms, independently researched and developed bioinformatics analysis platforms, vast databases as well as consistent and efficient innovative abilities supported by the multi-disciplinary research team, Genetron Health has registered multiple patents, including ‘One-Step Seq Method,’ and obtained NMPA approvals of various IVD devices and assays, which has led to accumulation of extensive R&D experience and registration applications with NMPA. Moreover, benefiting from its world-leading quality management system and rich clinical partnership resources, Genetron Health has established a full-cycle pharmaceutical R&D service system, which is capable of providing standardized full-chain services for its partners, consisting of multinational pharmaceutical companies, innovative pharmaceutical companies and biomedical CROs in the fields including early stage biomarker development, RWS, molecular testing for clinical trials, patient recruitment and filtering, and companion diagnostic development and commercialization.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191213005208/en/

CONTACT

Media:

Genetron Health

TAO Yuan

Email: yuan.tao@genetronhealth.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Hot Topics Recap: Coronavirus
  • Japan Ministry of Health, Labor and Welfare Approves Opdivo (nivolumab) for the Treatment of Patients with Unresectable Advanced or Recurrent Esophageal Cancer
  • Harbour BioMed Announces Completion of Phase 1 Study in China of HBM9161, an Anti-FcRn Antibody
  • Meiji Seika Pharma Co., Ltd:支持中国控制新型冠状病毒
  • Meiji Seika Pharma Co., Ltd: Support for Control of Novel Coronavirus in China